Has Haseeb Chaudhary, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,945 in general payments to Haseeb Chaudhary, MD across 55 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Haseeb Chaudhary, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Haseeb Chaudhary, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Haseeb Chaudhary, MD

Internal Medicine · West Reading, PANPI 1487215570

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 55 payments — averaging $35.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$577
AbbVie$347
Johnson & Johnson$293
Amgen$218
UCB, Inc.$168
E.r. Squibb & Sons, L.L.C.$88
plus $253 from 7 others

What the payments were for

Travel & lodging$26314%
Food & beverage$1,52578%
Education$1578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	6	$577
AbbVie	15	$347
Johnson & Johnson	6	$293
Amgen	7	$218
UCB, Inc.	5	$168
E.r. Squibb & Sons, L.L.C.	4	$88
Aurinia Pharma U.S., Inc.	3	$67
Pfizer	2	$48
AstraZeneca	2	$41
Lilly USA, LLC	2	$41
Organon	1	$21
GSK	1	$18
Merck	1	$17

How this compares

$1,945 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$16,325

Medicare patients

118

Services billed

164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Enbrel SureclickEtanercept	12	$90,698
TymlosAbaloparatide	15	$40,216
RasuvoMethotrexate/Pf	13	$6,959
Mycophenolate Mofetil	24	$2,178
Leflunomide	18	$1,951
MethotrexateMethotrexate Sodium	85	$1,789
Colchicine	26	$1,411
Hydroxychloroquine Sulfate	38	$1,259
Prednisone	117	$793
Allopurinol	41	$440
Celecoxib	14	$364
Alendronate Sodium	41	$152
Gabapentin	19	$119
Folic Acid	20	$82
Amlodipine Besylate	11	$7

Paid to pharmacies, not to this prescriber.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other internal medicine in West Reading